Business Context and Reporting Period
Company: Kiora Pharmaceuticals, Inc. (KPRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 25, 2022 (Event Date)
Reporting Period: Fiscal quarter ended March 31, 2022 (unfiled at time of notice)
Key Financial Metrics
This filing is a notice of delisting risk and does not contain specific financial performance data (revenue, profit, cash flow, margins, debt, or liquidity) for the current or prior periods. The filing references a restatement of financial statements for fiscal years 2020 and 2021 and interim periods in 2021 due to accounting errors, but does not disclose the restated figures within this document.
Material Changes and Events
- Nasdaq Non-Compliance: The Company received a notice from Nasdaq on May 25, 2022, stating it is no longer in compliance with Listing Rule 5250(c)(1) for failing to timely file its Form 10-Q for the quarter ended March 31, 2022.
- Reason for Delay: The delay is attributed to the preparation of an Amended Form 10-K for the fiscal year ended December 31, 2021. The audit committee identified inadvertent errors in accounting for certain contingent consideration, necessitating a restatement of financial statements for 2020, 2021, and interim periods in 2021.
- Previous Notification: The Company filed a Form 12b-25 Notification of Late Filing with the SEC on May 17, 2022.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 60 calendar days (until July 25, 2022) to regain compliance by filing the Form 10-Q or submitting a compliance plan to Nasdaq.
- Extension Possibility: If a compliance plan is submitted and accepted, Nasdaq may grant up to 180 days from the original due date (until November 21, 2022) to regain compliance.
- Appeal Rights: If Nasdaq rejects the compliance plan, the Company retains the right to appeal to a Nasdaq Hearings Panel.
- Current Listing Status: The notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the status of the Amended Form 10-K and Form 10-Q filings by the July 25, 2022 deadline.
- Review the upcoming restated financial statements to understand the magnitude of the "inadvertent errors" regarding contingent consideration.
- Monitor for any further communications from Nasdaq regarding the acceptance of a compliance plan or potential delisting proceedings.
- Confirm whether the restatement impacts the Company's liquidity position or ability to fund operations.